Harriette J Kahn Selected Research

monoclonal antibody D2-40

4/2008	Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
2/2007	Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer.
4/2005	Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium.
9/2002	A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors.
4/2002	Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harriette J Kahn Research Topics

Disease

14	Breast Neoplasms (Breast Cancer) 01/2015 - 08/2004
11	Neoplasms (Cancer) 01/2015 - 09/2002
3	Ductal Carcinoma 07/2013 - 03/2006
2	Carcinoma (Carcinomatosis) 07/2013 - 02/2007
2	Melanoma (Melanoma, Malignant) 04/2008 - 04/2005
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2008 - 03/2006
2	Disease Progression 09/2006 - 08/2004
1	Febrile Neutropenia 01/2015
1	Fatigue 01/2015
1	Pathologic Complete Response 01/2010
1	Inflammatory Breast Neoplasms 01/2010
1	Neoplasm Micrometastasis 07/2006
1	Neoplasm Metastasis (Metastasis) 07/2006
1	Carcinogenesis 11/2005
1	Circulating Neoplastic Cells 08/2004
1	Kaposi Sarcoma (Kaposi's Sarcoma) 04/2002
1	Hemangiosarcoma (Angiosarcoma) 04/2002

Drug/Important Bio-Agent (IBA)

5	monoclonal antibody D2-40IBA 04/2008 - 04/2002
4	Eosine Yellowish-(YS) (Eosin)IBA 01/2010 - 04/2005
4	Estrogen ReceptorsIBA 02/2007 - 01/2005
3	Hematoxylin (Haematoxylon)IBA 01/2010 - 04/2005
3	Oncogene Proteins (Oncogene Protein)IBA 03/2007 - 01/2005
3	Progesterone Receptors (Progesterone Receptor)IBA 02/2007 - 01/2005
3	DNA (Deoxyribonucleic Acid)IBA 03/2006 - 01/2005
2	Epirubicin (Ellence)FDA LinkGeneric 01/2015 - 01/2010
2	Docetaxel (Taxotere)FDA Link 01/2015 - 01/2010
2	RNA (Ribonucleic Acid)IBA 01/2015 - 01/2010
2	Immunoglobulin Fab FragmentsIBA 07/2013 - 01/2005
2	Biomarkers (Surrogate Marker)IBA 01/2010 - 01/2008
2	Monoclonal AntibodiesIBA 04/2008 - 04/2005
2	Proteins (Proteins, Gene)FDA Link 03/2007 - 11/2005
2	Formaldehyde (Formol)FDA Link 02/2007 - 03/2006
2	ParaffinIBA 02/2007 - 03/2006
2	Biological ProductsIBA 07/2006 - 08/2004
1	111In-DTPA-trastuzumabIBA 07/2013
1	Pharmaceutical PreparationsIBA 01/2010
1	trioctyl phosphine oxide (TOPO)IBA 01/2010
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 02/2008
1	Cyclin D1IBA 01/2008
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2008
1	S100 Calcium Binding Protein A7IBA 01/2008
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2007
1	CytokinesIBA 08/2007
1	thiamine triphosphorate (TTP)IBA 09/2006
1	Keratins (Keratin)IBA 07/2006
1	Endopeptidase K (Proteinase K)IBA 03/2006
1	Phenol (Carbolic Acid)FDA Link 03/2006
1	Small Interfering RNA (siRNA)IBA 11/2005
1	Ligases (Synthetase)IBA 11/2005
1	UbiquitinIBA 11/2005
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 11/2005
1	Immunoglobulin G (IgG)IBA 01/2005
1	Trastuzumab (Herceptin)FDA Link 01/2005
1	Indicators and Reagents (Reagents)IBA 08/2004

Therapy/Procedure

3	Therapeutics 07/2006 - 01/2005
1	Drug Therapy (Chemotherapy) 01/2010
1	Segmental Mastectomy (Lumpectomy) 01/2008
1	Lasers (Laser) 03/2006